A brain tumor diagnosis can change a person’s life in an instant, especially when the cancer is glioblastoma.
This cancer grows quickly, mixes with normal brain tissue and frequently comes back after treatment, which is why doctors have spent decades searching for safer and more effective ways to control it.
Standard care often involves an operation in which surgeons temporarily remove part of the skull and take out as much visible tumor as they safely can. Patients usually receive radiation and chemotherapy afterward, yet microscopic cancer cells can remain in the brain and begin growing again.
Some tumors also sit in places that are simply too dangerous to reach with a large operation. In those situations, doctors may use a technique that destroys the tumor from the inside with heat.
The treatment is called laser interstitial thermal therapy, commonly shortened to LITT. A surgeon makes a tiny opening in the skull, passes a narrow laser probe toward the tumor and uses MRI scans to watch its position in real time.
When the probe is correctly placed, the laser heats nearby tumor tissue until the cancer cells are destroyed. Because the opening is so small, patients can often recover much faster than they would after conventional open brain surgery.
Researchers at Washington University School of Medicine in St. Louis have now examined a large group of patients to learn when this laser approach appears to work best. Their analysis was published in the Journal of Clinical Oncology.
The study included 787 patients treated at Siteman Cancer Center and 24 other medical centers in the United States. Some had tumors that started in the brain, while others had cancers that began elsewhere in the body and later spread to the brain.
Rather than simply asking whether the laser procedure worked, the researchers looked for details that separated patients with better outcomes from those with poorer ones. Two patterns stood out: removing a very large share of the tumor appeared important, and treating some tumors earlier appeared to be better than waiting.
In people with newly diagnosed glioblastoma, survival was longer when the laser destroyed nearly all of the tumor. Patients in whom at least 91% of the tumor was treated had a median survival of about 2.1 years from diagnosis.
This does not mean every patient receiving the procedure will live that long. Glioblastoma behaves differently from person to person, and age, tumor biology, location, general health and response to other treatments can all change survival.
Even so, the finding is notable because glioblastoma has historically had a poor outlook despite surgery, radiation and chemotherapy. It also suggests that LITT might deserve study as an earlier treatment for selected patients instead of being viewed only as a last option when ordinary surgery is impossible.
The researchers found a different but equally useful lesson in patients with brain metastases. These tumors begin as cancers in organs such as the lung, breast or skin and later travel through the body to the brain.
Some brain metastases are treated first with focused radiation. If a suspicious area later appears on a scan, doctors sometimes watch it over time because radiation itself can cause changes that look like returning cancer.
The new analysis suggests there may be a cost to waiting too long when a growing tumor really does need laser treatment. Patients tended to do better when LITT was performed while the tumor was still small rather than after it had grown larger.
That finding could influence how doctors think about the timing of treatment, although it does not mean every small abnormality on an MRI should immediately be treated. Doctors still need to distinguish active cancer from harmless or treatment-related changes before recommending another procedure.
Recovery was another important part of the study. The average hospital stay after laser therapy was only about 32 hours, and most patients did not need intensive care or another hospital admission soon afterward.
Researchers also reported that the treatment generally preserved day-to-day quality of life. For people with advanced cancer, avoiding a long hospital recovery can matter almost as much as gaining additional time.
Dr. Eric C. Leuthardt, the study’s lead author and a neurosurgeon at Washington University, said the aim is to extend life while also helping patients spend more of that life outside the hospital. The research team believes the new information can help doctors select patients and plan treatment more carefully.
There are important limits to the findings. The study was not a randomized comparison proving that laser treatment is superior to open surgery, and patients receiving LITT may differ from other brain cancer patients in ways that affect how long they survive.
The apparent benefit from destroying at least 91% of a glioblastoma is therefore best understood as a strong association, not a guarantee or proof of cause and effect. Likewise, the finding that smaller metastases had better outcomes supports earlier consideration of treatment but does not establish the ideal treatment time for every patient.
Still, the study is valuable because it moves the conversation beyond whether LITT can be performed safely. It begins to answer the more useful question of how doctors can use the procedure in a way that gives patients the greatest possible benefit.
Future trials will need to compare treatment strategies more directly and examine how laser therapy works alongside radiation, chemotherapy, targeted drugs and immune-based treatments. If those studies confirm the current findings, a procedure once used mainly for difficult or recurrent tumors could become a more important part of brain cancer care.
If you care about cancer, please read studies that low-carb diet could increase overall cancer risk, and new way to increase the longevity of cancer survivors.
For more health information, please see recent studies about how to fight cancer with these anti-cancer superfoods, and results showing daily vitamin D3 supplementation may reduce cancer death risk.
Source: Washington University School of Medicine in St. Louis.
